PDC*line Pharma and partners receive financing from Walloon region

17 January 2024

Belgian clinical-stage biotech PDC*line Pharma today announced the selection of the PDC*neo+ project for funding by the Walloon region and BioWin, the health cluster for Wallonia.

This is the result of a call for proposals on R&D projects in the field of Advanced Therapy Medicinal Products (ATMP). Members of the project consortium will receive 8.1 million euros ($8.9 million) in funding, including 4.7 million euros for PDC*line Pharma. The total budget is 12.5 million euros.

The project aims to develop PDC*neo+, a personalized therapeutic vaccine for colorectal cancer using PDC*line Pharma's innovative PDC*line technology. Targeting unique neoantigens in each colorectal cancer patient, PDC*neo+ represents a ground-breaking approach in cancer immunotherapy.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK